ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
+$0.18 today
- Market cap
- $6.99B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
Volume 11.10M
Average 16.40M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
ImmunityBio, Inc.
NASDAQ:IBRX
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +678.6% | +86.0% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +678.6% over three years. Forward estimates point to Revenue at +86.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Moderna, Inc. NASDAQ:MRNA | $90.38B | $223.37 | Not rated | -7.9 | +791.46% |
BioNTech SE NASDAQ:BNTX | $21.22B | $85.60 | Not rated | -16.2 | -16.08% |
Iovance Biotherapeutics, Inc. NASDAQ:IOVA | $3.59B | $7.76 | Not rated | -4.6 | +235.32% |
Legend Biotech Corporation NASDAQ:LEGN | $3.24B | $17.50 | Not rated | -21.4 | -41.52% |
Vir Biotechnology, Inc. NASDAQ:VIR | $1.71B | $9.96 | Not rated | -3.0 | +59.53% |
Immunocore Holdings plc NASDAQ:IMCR | $1.55B | $29.94 | Not rated | -77.5 | -31.74% |
Immatics N.V. NASDAQ:IMTX | $956.17M | $6.39 | Not rated | -5.3 | -41.09% |
Allogene Therapeutics, Inc. NASDAQ:ALLO | $290.58M | $0.84 | Not rated | -2.7 | -46.22% |
Nkarta, Inc. NASDAQ:NKTX | $85.23M | $1.19 | Not rated | -2.0 | -35.26% |
Atara Biotherapeutics, Inc. NASDAQ:ATRA | $78.45M | $7.70 | Not rated | -14.7 | -52.04% |
Continue the stock analysis
Jump to another research area for this company.